Xvivo makes recommended public bid for Vivoline

The Board of Directors of Spago Nanomedical has decided that the company's resources will be focused on the development of Tumorad with the company's primary priority being the execution of the ongoing clinical study Tumorad-01 with the candidate drug 177Lu-SN201.

The board of directors of Senzime has resolved on a directed share issue of a maximum of 13 873 000 shares at the subscription price of SEK 6.20 per share.

For seriously ill children and adolescents, intravenous drip stands can significantly hinder mobility.

Getinge has announced an agreement to acquire 100% of Paragonix Technologies for an aggregated purchase price, including upfront and earn out payments, estimated to approximately USD 477 million. The acquisition aligns with Getinge’s broader strategy to expand its portfolio into high growth markets that complement and enhance its acute heart and lung support offering already […]

AlgoDx has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its sepsis detection software using an algorithm, NAVOY CDS. This milestone marks a major step forward in AlgoDx’s expansion into the U.S. market, states the company. NAVOY CDS NAVOY CDS is a software as a medical device (SaMD) designed to support […]

The acquisition aligns with Labquality’s international growth strategy and enables Labquality to grow its business in Sweden and to enter new markets like Norway and Denmark, it states. “Scandinavian CRO is a great addition to our Labquality family completing our CRO business platform. Now, we are a full service CRO company, and we can continue […]

Genovis has announced the successful divestment of its antibody business to Leinco Technologies, a developer of antibodies for research and diagnostics. The divestment follows a strategic review by Genovis, which identified the need to concentrate on its core enzyme business, it states. The antibody business, while valuable, was deemed non-core to the company’s long-term growth […]